Covance reported two additions to its clinical development services scientific leadership team with the appointments of Robert Wasserman, MD, as vice president and global therapeutic area head, Oncology and Rogelio Mosqueda-Garcia, MD, PhD, as global vice president, Early Clinical Services within Medical & Scientific Affairs. Both are based in Princeton, NJ.
Wasserman will be responsible for leading the scientific strategy for the oncology and hematology therapeutic areas. Before joining Covance, Wasserman worked at Hoffmann-La Roche as site head of academic alliances, Pharma Research and Early Development for the Translational Clinical Research Center.
Mosqueda-Garcia will provide scientific direction for the Clinical Pharmacology Services and Early Clinical Development groups. He also will work internally and externally to address issues of clinical pharmacology studies in patients, integration of biomarkers in early development, and the creation of new approaches to establish proof of concept in development programs of new drug candidates. Mosqueda-Garcia previously served as executive director in Clinical Pharmacology at AstraZeneca Pharmaceuticals.